You are here

Daiichi Sankyo

Biopharma's stock market winners of 2022 revealed

EP Vantage

Wed, 01/18/23 - 09:46 am

Vertex Pharmaceuticals

Sarepta Therapeutics

Horizon Therapeutics

10 clinical trials to watch in the first half of 2023

BioPharma Dive

Tue, 01/3/23 - 10:57 am

clinical trials

Alzheimer's disease

Huntington's disease

Nimbus Therapeutics

Moderna Therapeutics

Gilead Sciences

Big pharma’s new year catalysts

EP Vantage

Mon, 12/19/22 - 11:05 am

AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials

Clinical Trials Arena

Mon, 12/12/22 - 10:26 am

clinical trials

datopotamab deruxtecan

metastatic triple-negative breast cancer

SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla

Fierce Pharma

Fri, 12/9/22 - 10:54 am

Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate

Fierce Biotech

Fri, 12/9/22 - 10:46 am

antibody-drug conjugate

clinical trials

Gilead Sciences

Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences

NASDAQ.com

Thu, 12/8/22 - 10:03 am

Gilead Sciences

The problem with Her2-low testing

EP Vantage

Mon, 11/28/22 - 07:34 pm

HER2-low breast cancer

Cancer drugmaker Plexxikon gets new life as Opna Bio

BioPharma Dive

Tue, 11/22/22 - 10:38 am

Daiichi Sankyo’s Covid-19 vaccine trial meets primary endpoint

Clinical Trials Arena

Tue, 11/15/22 - 10:51 am

clinical trials

After nearly 20 years, Cyclacel kicks phase 3 leukemia drug back to Daiichi

Fierce Biotech

Thu, 11/10/22 - 10:39 am

Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu

Endpoints

Mon, 10/31/22 - 04:15 pm

non-small cell lung cancer

FDA grants priority review for Daiichi Sankyo’s AML medicine

Pharmaceutical Business Review

Tue, 10/25/22 - 10:37 am

priority review

acute myeloid leukemia

The gloom deepens for biopharma stocks

EP Vantage

Mon, 10/10/22 - 06:54 pm

biopharma stocks

CRISPR Therapeutics

Intellia Therapeutics

Sarepta Therapeutics

Roche nets FDA approval for HER2-low breast cancer test paired with AstraZeneca-Daiichi's Enhertu

Fierce Biotech

Wed, 10/5/22 - 07:07 pm

HER2-low breast cancer

Daiichi Sankyo's Ezharmia Becomes First EZH1/2 Inhibitor for Blood Cancer

BioSpace

Mon, 09/26/22 - 11:32 pm

relapsed or refractory adult T-cell leukemia/lymphoma

ESMO: Daiichi dazzles in lung cancer to dial up hopes for next ADC

Fierce Biotech

Mon, 09/12/22 - 10:43 am

small cell lung cancer

Seagen loses arbitration case to Daiichi Sankyo over cancer drug technology

BioPharma Dive

Sun, 08/14/22 - 10:50 pm

Pages